iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer. iPSirius: Illuminating the Path to Cancer Immunity
| Website | http://www.ipsirius.co.uk |
| Employees | 2 (1 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research |
| Keywords | Medical Research, Immuno Oncology, Treatment, Cancer Therapy, Clinical Trials, Clinical Stage, Drug Development, Biotechnology, Pharmaceutical, Healthcare, Therapeutics, Medicine, Regulatory Agency, Oncology, Immunotherapy, Biopharma, Clinical Research, Drug Discovery, Health Technology |
Looking for a particular iPSirius employee's phone or email?
Annelise Griscelli is the Co-Founder of iPSirius.
1 people are employed at iPSirius.